• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Dabigatran and myocardial infarction: a foggy scenario.达比加群与心肌梗死：情况不明。
Vasc Health Risk Manag. 2014 Jan 20;10:45-8. doi: 10.2147/VHRM.S57529. eCollection 2014.
2
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.达比加群治疗期间的心血管结局：按治疗方式对个体受试者数据进行的综合分析。
Vasc Health Risk Manag. 2013;9:599-615. doi: 10.2147/VHRM.S49830. Epub 2013 Oct 11.
3
Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.达比加群治疗患者心肌梗死数据解读的陷阱
J Cardiovasc Med (Hagerstown). 2015 Feb;16(2):142. doi: 10.2459/JCM.0000000000000087.
4
Cost of dabigatran for atrial fibrillation.达比加群酯用于治疗心房颤动的费用。
BMJ. 2011 Oct 31;343:d6980. doi: 10.1136/bmj.d6980.
5
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.新型口服抗凝药物在静脉血栓栓塞、心房颤动和急性冠状动脉综合征治疗中的应用。
Clin Appl Thromb Hemost. 2012 Sep;18(5):476-86. doi: 10.1177/1076029612438957. Epub 2012 Mar 2.
6
Increased risk of myocardial infarction with dabigatran: fact or fiction?达比加群导致心肌梗死风险增加：事实还是虚构？
J Cardiovasc Med (Hagerstown). 2014 Jan;15(1):19-26. doi: 10.2459/JCM.0b013e328364beb8.
7
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.用于心房颤动、静脉血栓栓塞性疾病和急性冠状动脉综合征的卒中预防的新型口服抗凝剂的最新综述。
J Am Heart Assoc. 2013 Oct 23;2(5):e000136. doi: 10.1161/JAHA.113.000136.
8
Dabigatran's 'real-world' data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials.
J Am Coll Cardiol. 2013 Sep 3;62(10):945-6. doi: 10.1016/j.jacc.2013.05.066. Epub 2013 Jun 27.
9
Reply: Dabigatran's 'real-world' data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials.回复：达比加群酯关于心肌梗死风险和胃肠道出血的“真实世界”数据与随机试验结果相矛盾。
J Am Coll Cardiol. 2013 Sep 3;62(10):946-7. doi: 10.1016/j.jacc.2013.05.067. Epub 2013 Jun 27.
10
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.达比加群酯用于预防心房颤动患者的卒中及全身性栓塞：英国国家卫生与临床优化研究所指南
Heart. 2012 Oct;98(19):1404-6. doi: 10.1136/heartjnl-2012-302101. Epub 2012 Jun 14.

本文引用的文献

1
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.达比加群治疗期间的心血管结局：按治疗方式对个体受试者数据进行的综合分析。
Vasc Health Risk Manag. 2013;9:599-615. doi: 10.2147/VHRM.S49830. Epub 2013 Oct 11.
2
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.口服直接凝血酶抑制剂使用致心肌梗死风险的随机对照试验的荟萃分析。
Am J Cardiol. 2013 Dec 15;112(12):1973-9. doi: 10.1016/j.amjcard.2013.08.027. Epub 2013 Sep 25.
3
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.非 ST 段抬高型急性冠脉综合征中用奥塔米沙班进行抗凝治疗和缺血事件：TAO 随机临床试验。
JAMA. 2013 Sep 18;310(11):1145-55. doi: 10.1001/jama.2013.277165.
4
Bivalirudin in acute coronary syndromes and percutaneous coronary intervention: should we use it?比伐卢定在急性冠脉综合征和经皮冠状动脉介入治疗中的应用：我们应该使用它吗？
Heart Lung Circ. 2013 Oct;22(10):793-800. doi: 10.1016/j.hlc.2013.05.636. Epub 2013 Jul 31.
5
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.在 ATLAS-ACS 2 TIMI 51 研究中，接受利伐沙班治疗的急性冠脉综合征患者中支架血栓形成减少。
J Am Coll Cardiol. 2013 Jul 23;62(4):286-90. doi: 10.1016/j.jacc.2013.03.041. Epub 2013 Apr 16.
6
Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner.载脂蛋白 E 缺陷小鼠凝血酶形成的遗传和药理学修饰以中性粒细胞依赖的方式决定动脉粥样硬化的严重程度和动脉血栓形成的发生。
PLoS One. 2013;8(2):e55784. doi: 10.1371/journal.pone.0055784. Epub 2013 Feb 7.
7
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.在随机评估长期抗凝治疗试验（RE-LY 试验）中，达比加群或华法林与抗血小板治疗同时使用。
Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.
8
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?达比加群对凝血酶生成的抑制作用弱于华法林：这是否可以解释它们在颅内出血和心肌梗死方面的差异效应？
J Thromb Thrombolysis. 2013 Feb;35(2):295-301. doi: 10.1007/s11239-012-0857-9.
9
Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.新型口服抗血栓药物的冠脉和死亡率风险：大型随机试验的荟萃分析。
BMJ Open. 2012 Oct 6;2(5). doi: 10.1136/bmjopen-2012-001592. Print 2012.
10
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.达比加群与急性冠脉事件高风险相关：非劣效性随机对照试验的荟萃分析
Arch Intern Med. 2012 Mar 12;172(5):397-402. doi: 10.1001/archinternmed.2011.1666. Epub 2012 Jan 9.

Dabigatran and myocardial infarction: a foggy scenario.

作者信息

Pontillo Daniele, Patruno Nicolino

机构信息

Division of Cardiology, Hospital Complex Belcolle, Pavilion Montefiascone Montefiascone, Italy.

Division of Cardiology, San Giuseppe Hospital, Albano Laziale (RM), Italy.

出版信息

Vasc Health Risk Manag. 2014 Jan 20;10:45-8. doi: 10.2147/VHRM.S57529. eCollection 2014.

DOI:10.2147/VHRM.S57529
PMID:24476689
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3901777/
Abstract
摘要